CONMEDCNMD
Recorded

CONMED Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration26 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Yuan LiMedTech Analyst

All right, why don't we get this session started? Thanks, everyone, for coming. My name is Young Li, one of the Jefferies MedTech analysts, and really pleased to be hosting management from CONMED. We have Pat Beyer, President and CEO, and John Gallagher, EVP and CFO of the company. Gentlemen, welcome to our conference.

Pat BeyerPresident and CEO

Thank you. Glad to be here.

John GallagherEVP and CFO

Yeah, thank you. All right, great.

Yuan LiMedTech Analyst

I guess, why don't we start off a little bit high level, because it's kind of topical. Some of the MedTech peer companies have kind of called out some market softness, especially for the more elective type of procedures within orthopedics. What's CONMED seeing from your perspective in terms of your end markets, both for the ortho business as well as for general surgery?

Pat BeyerPresident and CEO

Young, good question. Again, we're in different segments than what we typically are hearing companies talk about, total joints, hips, and knees, be that. We're seeing stability there, and we're seeing the same thing on the general surgery side. I would also say the size of our market share also tells us that we should be able to weather those headwinds that hit us better than a larger MedTech company with larger market share. Our outlook is stability, and we're not saying anything differently right now.

Yuan LiMedTech Analyst

Okay, great. Is it fair to assume that's what you're expecting for next year as well?

Yuan LiMedTech Analyst

We are, yeah. Good. I guess, wanted to focus on AirSeal.

Yuan LiMedTech Analyst

It's a topic that gets a lot of attention from investors. I guess, you are trying to expand into the laparoscopic segment more and more. How's that transition going, both in the U.S. and, I think, OUS, you do better and more laparoscopic procedures. How's the trend in the OUS side as well?

Pat BeyerPresident and CEO

Young, when we think about AirSeal, we think about it as a platform that helps us drive our global general surgery business. In quarter three, we grew 6.4%, so we really like where we're at globally. On the AirSeal side, we have two specific markets we target, soft tissue robotics and the world of laparoscopy. Both are growth opportunities, not just in the U.S., but also internationally. We have a history of driving penetration in the laparoscopic market internationally. We have pivoted in the U.S. in the last couple of years to include that in our portfolio of offense, not just the robotic side, but also the laparoscopic side, and we're seeing uptakes on that. What you're seeing from that is, you're seeing our capital sales in the U.S. accelerate from quarter one and quarter two, and continue to be strong for us.

Yuan LiMedTech Analyst

Okay. It's a big, relatively untapped opportunity. It's about 3 million procedures in the U.S. Where do you think that penetration can go? Can you sort of compare it relative to where you are on the robotic side?

Pat BeyerPresident and CEO

Yeah. So, we say we're 6%-7% penetrated in the U.S. on a TAM of about 3 million procedures. We see that continuing to grow. We believe we'll be in the double digit/higher double digit market share in the coming years. On the robotic side, the opportunity for us has been to partner with the soft tissue robotic companies where their portfolio takes care of every patient. We have been typically used in the robotic side on the more acute patients. So, our penetration on the robotic side has typically been in the 30%-40% range. There's no reason to say over time we wouldn't be in that type of market share, Young.

Yuan LiMedTech Analyst

Okay, great. What about the selling process? How different is it? I think, historically, your reps would just basically follow the Intuitive installs and then try to get a placement there. How is it different in the lap channel?

Pat BeyerPresident and CEO

In the lap channel, it shouldn't be any more different. The opportunity for us in the last years was robotics was growing fast, and we had enough to say grace over in that world. Now we're pivoting and going into laparoscopy, and in laparoscopy, we drive single-digit stable pressure laparoscopy. Better patient outcomes, better economic outcomes. The higher the acuity of the patient, the better the outcomes and the better the economic portfolio. New data that we're seeing is showing fast procedures, like a lap chole that are only 30 minutes, are also seeing clinical and economic value from an AirSeal portfolio. The other challenge I would say to our sales force has been to promote standardization. We do not want a surgeon to use CONMED insufflation on one cohort of patients and then move the AirSeal out of the room and bring in another insufflator.

Pat BeyerPresident and CEO

There's no reason that clinician has to do that. We want to standardize our insufflation portfolio across every procedure the hospital does.

Yuan LiMedTech Analyst

Okay, great. What about the OUS laparoscopic opportunity? Can you maybe talk about that market a little bit more? How big is it? How penetrated is it, the growth rate? And why is OUS laparoscopic relatively successful compared to the U.S.?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day